A study of deucravacitinib for teens with plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had stable plaque psoriasis for at least 6 months.
- Your psoriasis is moderate to severe (covering at least 10% of your body, with a certain score from your doctor).
- You are an adolescent (age 12 to 17, typically) and weigh at least 30 kg (66 pounds).
- You do not have other types of psoriasis (like guttate or pustular) or active serious infections.
- You have not taken deucravacitinib before and are not taking certain other medications.
- If you are female and able to have children, you must use highly effective birth control during the study and for a few days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medications for psoriasis (deucravacitinib and ustekinumab) over a long period. It's designed for people with moderate-to-severe psoriasis who also have certain risk factors for heart disease, like high blood pressure or diabetes.
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
This study compares two oral medications, deucravacitinib and apremilast, for adults with plaque psoriasis in Japan. It looks at how well each drug works in real-world use.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.